Change in the Pattern of Posttransplantation Anemia in Kidney Receptors: Sex Role in Recipients and Type of Donor

Cruz-Santiago, José; Velázquez-Zambrano, Carmen; Escamilla-Galindo, Pedro Aarón; Díaz-Rosas, Gabriela; Rojas-Rodríguez, Felipe Octavio; Venegas-Vera, A. Verner; Lòpez-Lòpez, Bibiana; Bernáldez-Gómez, Germán; Colbert, Gates B.; Velázquez, Jorge Luís Mejía; Aguilera-Vallejo, Jesús Eduardo; Hernández-Rivera, Juan Carlos H; Paniagua-Sierra, Ramón

doi:10.1016/j.transproceed.2019.12.050

Cited by 4 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were published by Mix [33] (OR 3.61 with 95% CI 1.60-8.15) and other authors [33][34][35][36], including a recent article by Cruz-Santiago y cols. [37], within one of the hospitals that participated in our study. When comparing the median age with those of several studies [5,10,13,15,16,31,38,39], it is up to 18 years younger, which is probably due to the fact that in our country there is a high incidence of chronic degenerative pathologies in young adults, leading to end-stage renal failure at an early age.…”

Section: Resultsmentioning

confidence: 99%

Risk factors for anemia after one year of kidney transplantation

Adame¹,

Pérez²,

Santiago³

et al. 2021

Trends in Transplant

View full text Add to dashboard Cite

Post renal transplant anemia (PTA) occurs in one out of every four patients and, by itself, increases mortality by six times at 10 years. The risk factors associated with its presence, during the first year, have been reported in some investigations with populations, generally different from Latin America. Therefore, a retrospective, longitudinal study was carried out that included 1,438 kidney transplant patients over six years in two public Medical Centers in Mexico. There were 39 deaths (2.7%) and 44 graft losses (3.1%) before one year of follow-up, who left the study. In the 1,355 cases that continued, a prevalence of anemia of 15.5% (n = 210) was found at 12 months. In the bivariate analysis with the PTA at one year, the cadaveric origin of the graft resulted in an OR of 2.24, 95% CI (1.65-3.05) and for creatinine (Cr)> 2.0mg / dL at 6 months, OR of 4.18, 95% CI (2.66-6.56). With Cr> 2.0mg / dL; At 12 months, an OR of 5.55 was obtained, 95% ). Height, baseline Cr, as well as female sex, had a statistically significant relationship with the outcome. In the multivariate model performed, the cadaveric donor, the female sex, and the Cr> 2.0mg / dL at 6 and 12 months predicted anemia at one year. It is concluded that Cr> 2.0 mg / dL, the female sex and the cadaveric graft are the main risk factors for anemia, one year after kidney transplantation.

show abstract

Section: Resultsmentioning

confidence: 99%

Risk factors for anemia after one year of kidney transplantation

Adame¹,

Pérez²,

Santiago³

et al. 2021

Trends in Transplant

View full text Add to dashboard Cite

show abstract

“…Posttransplant anemia (PTA) is defined as a hemoglobin (Hb) level <13 mg/dL in men and <12 mg/dL in women, and its prevalence varies from 20% to 70% [1][2][3]. Patients can be classified into two types based on the time of onset those with early PTA (within the first 6 months) and those with late PTA (>6 months posttransplant) [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

“…The occurrence of early PTA is reportedly associated with intraoperative factors, types of donors, and infections [2,7]. In contrast, the occurrence of late PTA is associated with chronic allograft nephropathy, immunosuppression, inhibitors of the reninangiotensin system, and second kidney transplants [2,8]. PTA is significantly associated with cardiovascular disorders, graft loss, and mortality [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Roxadustat for Patients with Posttransplant Anemia: A Narrative Review

Tang,

Liu,

et al. 2023

Kidney Dis

View full text Add to dashboard Cite

Background: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating anemia in chronic kidney disease patients, has been approved in China, Japan, South Korea, Chile, and Europe. Roxadustat is involved in HIF degradation, which can stimulate endogenous erythropoietin (EPO) production and improve iron utilization. Besides, roxadustat can promote dietary iron uptake and transport. In comparison with traditional erythropoiesis-stimulating agent (ESA) treatment, it might reduce cardiovascular risk and mortality as it causes only a slight increase in the plasma EPO level. Phase II and III clinical trial reports have shown that roxadustat is effective for treating chronic kidney disease patients. The role of roxadustat in kidney transplant recipients (KTRs) needs to be examined as patients with chronic kidney disease are different from those receiving renal transplants. Summary: Clinical trials have demonstrated that roxadustat effectively increases and maintains hemoglobin levels in patients with dialysis-dependent and non-dialysis-dependent chronic kidney disease by stimulating endogenous EPO production and optimizing iron utilization. Roxadustat has recently been used effectively to treat patients with EPO-resistant anemia. It has also been used for treating patients with post-transplant anemia (PTA), which is a prognostic factor for mortality in kidney transplant recipients with an iron deficiency and impaired glomerular filtration rate. Here, we examined the findings of four studies in a narrative review and discussed our perspectives regarding this field of study. Key Messages: Roxadustat significantly improves hemoglobin levels without affecting renal function in KTRs with PTA. It also enhances iron utilization by decreasing ferritin and hepcidin levels and increasing total iron binding capacity, transferrin, and serum iron levels. Roxadustat ameliorates anemia and inflammation, and might have reno-protective effects in KTRs.

show abstract

“…El monitoreo de los programas de trasplante renal es útil en la detección de oportunidades para incrementar el número de procedimientos y mejorar las tasas de resultados exitosos [15][16][17][18] . El monitoreo es particularmente importante en poblaciones como la mexicana, que tiene una incidencia elevada de enfermedad renal crónica terminal, muchas veces sin un diagnóstico, por lo cual se ha desarrollado enfermedad renal crónica [19][20][21] , además de poca disponibilidad de donantes vivos y cadavéricos 7 .…”

Section: Introductionunclassified